Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

Published byAurora Aaltonen Modified over 5 years ago

Similar presentations

Presentation on theme: "The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,"— Presentation transcript:

1 The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella, PhD, Nadia Coakley, MLIS, Susanna Cheng, MD, Richard Gregg, MD, Yee C. Ung, MD, Peter M. Ellis, M.B.B.S., PhD  Journal of Thoracic Oncology  Volume 11, Issue 7, Pages (July 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Overall survival for pemetrexed versus no pemetrexed for systemic maintenance in non–small cell lung cancer. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Progression-free survival for pemetrexed versus no pemetrexed for systemic maintenance in non–small cell lung cancer. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Overall survival for pemetrexed versus no pemetrexed for systemic maintenance in nonsquamous non–small cell lung cancer. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Progression-free survival for pemetrexed versus no pemetrexed for systemic maintenance in nonsquamous non–small cell lung cancer. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 5 Overall survival for epidermal growth factor receptor (EGFR) versus no EGFR for systemic maintenance in non–small cell lung cancer. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

7 Figure 6 Progression-free survival for epidermal growth factor receptor (EGFR) versus no EGFR for systemic maintenance in non–small cell lung cancer. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

8 Figure 7 Overall survival and epidermal growth factor receptor mutation status. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

9 Figure 8 Progression-free survival and epidermal growth factor receptor mutation status. Red squares represent the effect estimate and weight for each study. Black diamonds represent the overall effect estimate. SE, standard error; IV, inverse variance; CI, confidence interval. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery  Åslaug Helland, MD, PhD, Hege Marian Skaug, MSc, Lilach Kleinberg,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Similar presentations

Ads by Google